Finanzen von Regenxbio Inc (RGNX)RGNXRegenxbio Inc

Evaluating the bottom line, REGENXBIO Inc. maintains a gross margin of 99.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.09%, while the net margin is 21.02%. These profitability ratios, combined with a Return on Equity (ROE) of -137.63%, provide a clear picture of how effectively RGNX converts its operational activities into shareholder value.

In the context of the broader market, RGNX competes directly with industry leaders such as ENTX and EOLS. With a market capitalization of $534.05M, it holds a leading position in the sector. When comparing efficiency, RGNX's gross margin of 99.04% stands against ENTX's N/A and EOLS's 66.19%. Such benchmarking helps identify whether REGENXBIO Inc. is trading at a premium or discount relative to its financial performance.

Regenxbio has shown fluctuating financial performance with a gross margin of 99.04% in Q2 2026, indicating strong profitability potential. However, it reported a net income loss of $90.05 million in Q1 2026, highlighting ongoing financial challenges.